Lasofoxifene Explored in ESR1-Mutated ER+/HER2- Breast Cancer
Investigators are exploring whether lasofoxifene can stop disease progression in women with advanced or metastatic estrogen receptor (ER)–positive, HER2-negative breast cancer with an ESR1 mutation in the multicenter phase II ELAINE trial (NCT03781063).
Source: OncLive